Predicting response to hormone therapy before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests whether we can predict how well hormone therapy works before surgery for early-stage breast cancer. It may help women with estrogen receptor-positive, HER2-negative or HER2-low breast cancer avoid or tailor treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with invasive breast cancer that is estrogen receptor-positive (more than 10% of cells) and HER2-negative or HER2-low.
- Your breast cancer is early stage (stage 1 to 3) and can be removed with surgery.
- You are able to take oral medications and are willing to follow the study schedule.
- You are 21 years old or older.
- You understand the study and can give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how the tumor responds, aiming to improve outcomes while reducing side effects.
This study looks at whether biopsy test results can help predict how well hormone therapy will work for advanced or recurrent endometrial cancer. It may help doctors choose the most effective hormonal treatment sooner.
Hear when a new Breast Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.